Cecile Geuijen

Cecile Geuijen

Company: Merus

Job title: Chief Scientific Officer


The Bispecific Antibody MCLA-129 Impairs EGFR Inhibitor Resistant NSCLC Tumor Growth by Targeting EGFR & c-MET 11:30 am

Exploring the upregulation of c-MET signaling has been associated with resistance to EGFR inhibition Delving into MCLA-129: a bispecific antibody that blocks the signaling of EGFR as well as c-MET, to inhibit tumor growth and survival Understand how MCLA-129 utilizes ADCC-enhancement technology, which increases its cell-killing potential by immune cellsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.